Skip to content
Screener

Novavax NVAX Business Segments — Net income (loss)

Similar metrics at other companies

Marvell Technology, Inc. logo
MRVLReportable Segment — Net income (loss)
$34.5M-80.6%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Net income (loss)
-$32.83M
UiPath logo
PATHReportable Segment — Net income (loss)
$22.53M+200%
Calix logo
CALXReportable Segment — Net income (loss)
$17.11M+8,698%
LPR
LPROReportable Segment — Net income (loss)
-$460K-175%
CuriosityStream logo
CURIReportable Segment — Net income (loss)
-$1.33M-516%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Other income, net8,91911,90220,74421,957
Income (loss) before income tax expense(51,676)107,454(60,182)627,300
Income tax expense1,7119462,6962,146
Net income (loss)$(53,387)$106,508$(62,878)$625,154
Net income (loss) per share:
Basic$(0.32)$0.66$(0.38)$3.87
Diluted$(0.32)$0.62$(0.38)$3.55
Weighted average number of common shares outstanding:

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's business segments — net income (loss)?
Novavax (NVAX) reported business segments — net income (loss) of -$53.39M in Q2 2026.
How has Novavax's business segments — net income (loss) changed year-over-year?
Novavax's business segments — net income (loss) decreased by 150.1% year-over-year, from $106.51M to -$53.39M.
What is the long-term trend for Novavax's business segments — net income (loss)?
Over 3 years (2022 to 2025), Novavax's business segments — net income (loss) has grown at a -12.5% compound annual growth rate (CAGR), from -$657.94M to $440.3M.
What does business segments — net income (loss) mean?
Represents the final profit or loss generated by the reportable segment after accounting for all revenues, cost of sales, operating expenses, and other segment-specific items. It serves as the primary measure of the segment's overall financial health and its contribution to the company's total profitability.

Ask your AI about Novavax's business segments — net income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude